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Abstract
Background:  Intra-articular hyaluronic acid represents a substantive addition to the therapeutic
armamentarium in knee osteoarthritis. We examined the effect of dietary supplementation with a natural
extract of chicken combs with a high content of hyaluronic acid (60%) (Hyal-Joint®) (active test product,
AP) on pain and quality of life in subjects with osteoarthritis of the knee.
Methods: Twenty subjects aged ≥40 years with knee osteoarthritis (pain for at least 15 days in the
previous month, symptoms present for ≥6 months, Kellgren/Lawrence score ≥2) participated in a
randomized double-blind controlled trial. Ten subjects received AP (80 mg/day) and 10 placebo for 8
weeks. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and quality of
life by the Short Form-36 (SF-36v2) were administered at baseline and after 4 and 8 weeks of treatment.
Results: WOMAC pain (primary efficacy variable) was similar in both study groups (mean [SD]) with 6.6
(4.0) points in the AP group and 6.4 (2.7) in the placebo group (P = 0.943). As compared with baseline,
subjects in both groups showed statistically significant improvements in WOMAC pain, stiffness, physical
function subscales, and in the aggregate score, but the magnitude of changes was higher in the AP group
for WOMAC physical function (-13.1 [12.0] vs. -10.1 [8.6], P = 0.575) and total symptoms (-18.6 [16.8] vs.
-15.8 [11.4], P = 0.694). At 4 weeks, statistically significant mean changes compared with baseline were
observed in the SF-36v2 scales of role-physical, bodily pain, social functioning and role-emotional among
subjects in the AP group, and in physical functioning, bodily pain, and social functioning in the placebo
group. At 8 weeks, changes were significant for role-physical, bodily pain, and physical component
summary in the AP group, and for physical functioning and role-emotional in the placebo arm. Changes in
bodily pain and social functioning were of greater magnitude in subjects given AP.
Conclusion: This pilot clinical trial showed that daily supplementation with oral hyaluronic acid from a
natural extract of chicken combs (Hyal-Joint®) was useful to enhance several markers of quality of life in
adults with osteoarthritis of the knee. The results warrant further study in larger sample sizes.
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Background
Osteoarthritis, the most common type of arthritis, is char-
acterized by slow degradation of cartilage, pain, and
increasing chronic disability. Osteoarthritis is a frequent
cause of morbidity, functional limitations, and loss of
autonomy in the second half of human life. Moreover, the
disease is widely recognized to interfere with several
aspects of an individual's life, including functional and
social activities, body image, and psychological well-
being [1]. Osteoarthritis of the knee is especially common
and is a major cause of disability requiring extensive utili-
zation of health care resources [2,3]. Medical interven-
tions can be directed toward different stages of the disease
process: patient education (e.g., weight reduction), exer-
cise, analgesics, traditional and cyclooxygenase-2-selec-
tive nonsteroidal antiinflammatory drugs (NSAIDs), and
eventually orthopedic surgery, including joint replace-
ment. The reassessment of the central role of NSAIDs in
the treatment of osteoarthritis because of suboptimal
effectiveness and questions about safety [4,5] has favored
the screening and development of drugs that could inter-
fere directly with the disease process, aiming at protection
and regeneration of the cartilage. Chondroprotection is a
new field in the management of osteoarthritis that is
designed to improve cartilage repair as well as enhance
joint remodelling [6-8]. The orally administered glu-
cosamine and chondroitin sulfate, natural components of
articular cartilage, are examples of agents which may both
reduce the symptoms of pain associated with osteoarthri-
tis and have an impact on disease progression [9-12].
Hyaluronic acid or hyaluronan (sodium hyaluronate)
(HA), a heteropolysaccharide comprised of a variable
number of repeating units of D-glucuronic acid and N-
acetylglucosamine, is synthesized by synoviocytes, fibrob-
lasts, and chondrocytes. HA is present in the synovial fluid
and the extracellular matrix of cartilage, and is responsible
for the viscoelasticity and lubricating properties of syno-
vial fluid. It has recently been shown that HA performs a
multitude of biophysical, biochemical, and cell regulatory
roles in joint synovial tissues [13-15]. In osteoarthritis, the
concentration of synovial fluid is reduced and the viscoe-
lastic properties of the fluid are compromised, increasing
susceptibility of cartilage to injury. Intra-articular treat-
ment with HA (viscosupplementation) has become
widely accepted to reduce joint pain in osteoarthritis [16].
The original rationale for the use of intra-articular injec-
tion of HA was to increase the viscosity of the synovial
fluid. The observation that the clinical result exceeded the
life span of the HA exogenously administered into the
joint supports the view that effects other than biomechan-
ical properties could explain its therapeutic effectiveness.
A large number of studies have been published demon-
strating the positive and long lasting effects of intra-artic-
ular HA treatment in subjects with knee osteoarthritis [17-
20]. A recent systematic review of 76 randomized control-
led trials concluded that viscosupplementation is an effec-
tive treatment for osteoarthritis of the knee with beneficial
effects on pain, function and patient global assessment
[21].
These data support the use of the HA class products in the
treatment of knee osteoarthritis. On the other hand, there
is an increasing interest in the benefits of dietary supple-
ments as therapeutic agents in osteoarthritis [22]. Numer-
ous dietary supplements that may influence osteoarthritis
pathophysiology, including glucosamine, chondroitin
sulfate, avocado-soybean unsaponifiables, vitamins and
minerals, methylsulfonylmethane, phytochemicals and
plant extracts have been tested in clinical trials [23,24].
However, evidence of use of HA in oral formulations for
symptoms of knee osteoarthritis is lacking. Therefore, a
pilot randomized placebo-controlled trial was designed to
assess the effect of dietary supplementation with a natural
extract of chicken combs with a high content of
hyaluronic acid (Hyal-Joint®) on pain relief and quality of
life in subjects with osteoarthritis of the knee.
Methods
Study design
A randomized, double blind, placebo-controlled single-
center study was designed to assess the efficacy and safety
of Hyal-Joint® (active test product, AP) compared to pla-
cebo for pain relief and improvement of quality of life in
adult subjects with osteoarthritis of the knee. The active
test product is a dietary ingredient that consists of an
extract of chicken combs containing HA (60–70%) and
hydrolyzed proteins mostly collagen and other polysac-
charides. The duration of the study was 8 weeks. The study
took place from June 2005 to April 2006 in the United
States and involved the participation of a single clinical
service organization center (Miami Research Associates).
The study protocol was approved by the IntegReview Eth-
ical Review Board (Austin, Texas), and was conducted in
accordance with the principles of the Declaration of Hel-
sinki and its amendments. Written informed consent was
obtained from all participants prior to enrollment in the
study.
Eligibility
Male and female subjects of any race, aged 40 years or
over, with symptomatic osteoarthritis of the knee were eli-
gible provided that subjects experienced pain for at least
15 of the 30 days prior to the start of the study, symptoms
had been present for at least 6 months, and a confirma-
tory X-ray diagnosis (Kellgren/Lawrence score ≥ 2) within
the previous 6 months was available. Exclusion criteria
were: known allergy to chicken (sodium hyaluronate is
derived from chicken combs), corn, potato, rice or cellu-
lose (derived from wood pulp); any inflammatoryNutrition Journal 2008, 7:3 http://www.nutritionj.com/content/7/1/3
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arthritic condition; multiple sclerosis or autoimmune dis-
order; treatment with oral corticosteroids within 4 weeks
before screening; intra-articular corticosteroids in the tar-
get joint within 3 months before screening; significant
injury to the target joint within the past 12 months; pres-
ence of any clinically significant medical condition judged
by the investigator to preclude the patient's inclusion in
the study; renal dysfunction (serum creatinine concentra-
tion > 1.5 times the upper limit of normal); liver dysfunc-
tion (serum alkaline phosphatase and aminotransferases
> 2 times the upper limit of normal); and participation in
a clinical study in the previous 30 days. Pregnant women,
nursing mothers, or women of childbearing potential not
using adequate methods of contraception were also
excluded. A urine pregnancy test was performed before
enrollment. New onset use of glucosamine, chondroitin
sulfate, methylsulfonylmethane, or milk protein-based
dietary supplements was not allowed. Subjects using these
dietary products and willing to continue had to maintain
stable doses within 3 months before screening and
throughout the course of the study.
Treatment and patient evaluation
Study participants attended a screening visit (visit 1),
which included medical history, physical examination,
laboratory tests, radiographic confirmation of Kellgren/
Lawrence score ≥ 2, assessment of the use of concomitant
medication and/or dietary supplements, urine pregnancy
test (when applicable), and first signing the informed con-
sent. Subjects were instructed to discontinue or taper off
gradually any treatment with NSAIDs, cyclooxygenase-2
inhibitors, or analgesics with the exception of acetami-
nophen, to ensure a minimum 3-day drug-washout
period and were scheduled to return to the study center in
7 days for the baseline/randomization visit.
All eligible participants were sequentially assigned to one
of the two masked products according to a predetermined
computer-generated randomization schedule. Subjects
were randomized (1:1) to Hyal-Joint® (Bioibérica, Barce-
lona, Spain), 80 mg, or matched placebo capsules. Sub-
jects were instructed to take one capsule a day, in the
morning immediately after breakfast. The study product
was dispensed to subjects at each visit to cover the period
of time until the next visit. On the other hand, patients
were instructed to take rescue medication (paracetamol
500 mg) as needed with no more than four tablets (Tyle-
nol) per day. The use of rescue medication was assessed by
the pill return (pill count) method at each visit.
Assessments were performed at baseline (visit 2) and at 4
weeks (visit 3) and 8 weeks (visit 4) after initiation of the
treatment. The Western Ontario and McMaster Universi-
ties Osteoarthritis Index (WOMAC 3.0 Index) and the
Short Form-36 (SF-36v2, Acute US Version 2.0) question-
naires were administered at each visit. The WOMAC is a
disease-specific, self-administered questionnaire that
evaluates three dimensions: pain, stiffness, and physical
function with 5, 2, and 17 questions, respectively. Each
question is rated on an ordinal scale of zero to four, with
lower scores indicating minimal symptoms or physical
disability. The three subscales can be scored separately or
as a composite measure (aggregated total symptoms). The
SF-36v2 is a multi-purpose, short-form health survey with
36 questions. The SF-36v2 yields an 8-scale profile of
functional health and well-being scores as well as psycho-
metrically-based physical and mental health summary
measures and a preference-based health utility index. The
SF-36v2 yields information on physical health (com-
prised of physical functioning, role-physical, bodily pain,
and general health) and mental health (comprised of
vitality, social functioning, role-emotional, and mental
health). Finally, the physical (PCS-36) and the mental
(MCS-36) component summaries can be calculated.
Efficacy and safety parameters
The primary efficacy variable was the comparative differ-
ence between the AP and the placebo arms in scores of the
pain subscale of WOMAC and bodily pain of SF-36v2 at
week 8. Secondary efficacy variables included the compar-
ative difference between AP and placebo groups for all
other WOMAC and SF-36v2 subscales, and the change
over 8 weeks compared with baseline for the WOMAC
and SF-36v2 subscales recorded in each study group.
At the end of the study (at 8 weeks), a subjective accept-
ance questionnaire was administered to determine the
overall acceptability of the study products ("Do you believe
the product you were taken during the study decreased your
joint pain?" yes/no; "Do you believe the product you were
taken during this clinical trial decreased any muscle aches that
you experience?" yes/no). In addition, subjects were asked
"Do you think you were taking the active product or placebo?".
Tolerability and safety parameters were the incidence and
severity of adverse events reported throughout the study
as well as changes in blood pressure, heart rate, and labo-
ratory tests including complete blood cell count and bio-
chemical profile. Treatment compliance was also
recorded. Non-compliance was defined as taking less than
80% of the prescribed course of the study product. Use of
rescue medication (paracetamol 500 mg) during the study
period was also checked.
Statistical analysis
A sample size of 20 subjects (10 per group) provided 80%
power at the alpha level of 0.05 to detect a mean change
over time that is about equal to the within-group standard
deviations for the change over time in score points for
WOMAC and SF-36v2 endpoints, which were estimatedNutrition Journal 2008, 7:3 http://www.nutritionj.com/content/7/1/3
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from previous studies in subjects with osteoarthritis con-
ducted at the clinical service organization center.
All randomized subjects were included in the intent-to-
treat population. The ITT population was defined as all
subjects who received the product and who had some fol-
low-up evaluation. It includes subjects who dropped out
of the study, were removed or lost to follow-up, or were
seriously non-compliant with the regimen specified in the
protocol. The efficacy (per-protocol) population con-
sisted of subjects who completed all visits, and who were
suitably compliant with the prescribed regimen (supple-
ment or placebo), with an overall compliance rate
between 80% and 120% inclusive. Last observation car-
ried forward (LOCF) imputation method was performed
for missing efficacy variables in the intent-to-treat and
per-protocol analyses (PP). The safety population
included all subjects who were randomized and received
at least one dose of study product and for whom any
safety follow-up evaluation (physical examination, labo-
ratory tests, adverse events, subjective comments) were
obtained.
Baseline characteristics in the two study groups were com-
pared with the Student's t test of the Mann-Whitney U test
for continuous variables, and with the chi-square (χ2) test
or the Fisher's exact test for categorical variables. Changes
over time from baseline to each subsequent visit within
each study group were assessed for significance by the
paired Student's t  test or the non-parametric Wilcoxon
signed-rank test. Statistical significance was set at P < 0.05.
Results
Study population
Of the 36 potential participants phone-screened, 16 were
not enrolled because of lack of eligibility at the screening
visit (n = 15) and lost to follow-up before the baseline/
randomization visit (n = 1). Therefore, the study popula-
tion included 20 subjects, 9 men and 11 women, with a
mean (SD) age of 56.3 (9.0) years (range 42–73 years). A
total of 11 subjects were randomized to the active supple-
ment and 9 to placebo. However, three subjects in the AP
arm discontinued the study because of personal or profes-
sional reasons unrelated to the study. One subject in the
placebo arm discontinued the study due to restrictions
imposed by his work schedule. Data of the remaining 16
evaluable subjects were included in the PP data set. At
baseline, there were no significant differences in demo-
graphic data, anthropometric measures, vital signs, and
scores of the WOMAC and SF-36v2 instruments between
subjects assigned to the active supplement and those
assigned to placebo (Table 1). Results of laboratory tests
were within normal ranges in both study groups.
Efficacy
With regard to results of the WOMAC Index, the compar-
ison of mean (SD) scores for the pain dimension between
the study groups (primary efficacy variable) did not show
statistically significant differences (AP 6.3 [4.0]; placebo
6.4 [2.7], P = 0.943). However, within-group differences
for pain, WOMAC physical function, stiffness, and aggre-
gated total symptoms score as compared with baseline
were statistically significant at any (or both) of the follow-
up visits. On the other hand, the magnitude of mean (SD)
changes from baseline to week 8 was higher for subjects
treated with AP compared with placebo for WOMAC
physical function (-13.1 [12.0] vs -10.1 [8.6]) and total
symptoms (-18.6 [16.8] vs -15.8 [11.4]), although these
between-group differences were not statistically signifi-
cant. However, changes from baseline to week 4 for phys-
ical function (-8.1 [6.3], P = 0.008) and total symptoms
score (-10.1 [9.6], P = 0.20) achieved statistical signifi-
cance only in the AP group. Detailed results of the
WOMAC Index are shown in Table 2.
For the primary efficacy endpoint of the SF-36v2 (bodily
pain), differences between the study groups at week 8
were not statistically significant (AP 44.9 [10.1]; placebo
38.6 [5.4], P = 0.143), although subjects in the active sup-
plement group scored higher than those given placebo.
Within-group changes for bodily pain from baseline to
week 4 were statistically significant in both study groups;
however, changes from baseline to week 8 were only sta-
tistically significant in the AP arm (11.1 [9.6], P = 0.013)
(Figure 1). Individualized results of dimensions of physi-
cal health and mental health of the SF-36v2 questionnaire
are detailed in Tables 3 and 4, respectively. With regard to
PCS-36 (Figure 2), mean scores in the AP arm improved
significantly from 36.1 (6.8) at baseline to 42.3 (7.0) at
the end of the study (mean change 6.1 [5.2], P = 0.012),
whereas in subjects given placebo scores increased from
33.9 (6.5) at baseline to 37.5 (6.9) at week 8 (mean
change 3.6 [4.5], P = 0.059). Neither within-group nor
between-group differences for MCS-36 were observed.
The mean (SD) number of capsules of acetaminophen
used per week was higher among subjects assigned to pla-
cebo (4.3 [3.6]) than among those using the active supple-
ment (2.0 [3.0]) (P = 0.184), although this was not
significant. Use of rescue medication during the course of
the study is shown in Table 5. Additionally, more subjects
in the AP group compared with placebo answered affirm-
atively to perceived improvement in joint pain (75% vs
50%) and muscle aches (75% vs 38%). Sixty-two percent
of subjects in the active supplement group thought they
had received AP and 50% in the placebo group thought
they were in the comparator arm.Nutrition Journal 2008, 7:3 http://www.nutritionj.com/content/7/1/3
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Table 2: WOMAC Index scores during the study period in 16 evaluable subjects
Study groups and time points WOMAC Index scores, mean (SD)
Pain Stiffness Physical function Total symptoms
Hyal-Joint® (n = 8)
Baseline 10.4 (3.6) 4.2 (1.0) 36.3 (7.7) 50.9 (12.0)
Week 4 8.8 (3.4) 3.9 (1.6) 28.1 (9.2) 40.8 (13.6)
Week 8 6.3 (4.0) 2.9 (1.9) 23.1 (15.1) 32.3 (20.8)
Change baseline vs week 4 -1.6 (2.7) -0.4 (1.5) -8.1 (6.3) -10.1 (9.6)
P value 0.135 0.504 0.008 0.020
Change baseline vs week 8 -4.1 (3.4) -1.4 (2.0) -13.1 (12.0) -18.6 (16.8)
P value 0.012 0.092 0.018 0.016
Placebo (n = 8)
Baseline 10.4 (2.7) 4.5 (1.9) 37.4 (10.6) 52.3 (13.6)
Week 4 8.3 (3.0) 3.5 (1.9) 30.4 (10.7) 42.1 (17.7)
Week 8 6.4 (2.7) 2.9 (1.0) 27.3 (10.7) 36.5 (13.7)
Change baseline vs week 4 -2.1 (3.3) -1.0 (2.1) -7.0 (10.8) -10.1 (15.3)
P value 0.113 0.227 0.110 0.103
Change baseline vs week 8 -4.0 (2.8) -1.6 (0.9) -10.1 (8.6) -15.8 (11.4)
P value 0.005 0.002 0.012 0.006
Table 1: Baseline characteristics of the study subjects
Variable Study group P value
Hyal-Joint® (n = 11) Placebo (n = 9)
Men/women 4/7 5/4 0.653
Age, years, mean (SD) 57.7 (10.1) 54.6 (7.7) 0.448
Ethnicity 0.361
Black 0 1
Caucasian 1 1
Hispanic 10 6
Height, cm, mean (SD) 164.7 (6.1) 164.1 (10.8) 0.889
Weight, kg, mean (SD 79.1 (26.3) 80.9 (20.7) 0.867
Heart rate, beats/min, mean (SD) 75.5 (12.3) 75.7 (12.4) 0.970
Systolic BP, mm Hg, mean (SD) 122.8 (16.4) 135.6 (21.7) 0.152
Diastolic BP, mm Hg, mean (SD) 77.8 (8.9) 84.3 (10.4) 0.148
Rescue medication use (paracetamol 500 mg)*
No. capsules (range) 4 (0–19) 9 (0–29) 0.425
Mean (SD) 6.8 (7.3) 9.9 (9.6)
WOMAC scores, mean (SD)
Pain 10.4 (3.0) 10.1 (2.7) 0.848
Stiffness 4.4 (1.0) 4.4 (1.0) 0.862
Physical function 37.7 (7.4) 35.4 (11.5) 0.597
Aggregated total symptoms 52.5 (10.8) 50.0 (14.4) 0.667
SF-36v2 scores, mean (SD)
Physical functioning 30.8 (8.5) 27.1 (8.5) 0.342
Role-physical 35.3 (8.3) 41.9 (7.8) 0.084
Bodily pain 33.2 (4.8) 36.9 (4.8) 0.100
General health 44.1 (12.3) 45.4 (10.3) 0.814
Vitality 49.0 (11.3) 50.4 (11.7) 0.791
Social functioning 37.5 (12.0) 43.5 (11.3) 0.268
Role-emotional 36.1 (12.6) 40.3 (12.9) 0.467
Mental health 40.3 (19.7) 47.5 (9.5) 0.326
Physical component summary (PCS-36) 34.8 (6.3) 34.6 (6.4) 0.947
Mental component summary (MCS-36) 43.6 (17.5) 50.6 (11.2) 0.317
*Between screening and randomization visits.Nutrition Journal 2008, 7:3 http://www.nutritionj.com/content/7/1/3
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Safety and tolerability
Three adverse events were observed during the study
period. One subject in the AP group complained of acute
non-target knee pain, unrelated to the study product, and
voluntarily dropped out of the study. The two adverse
events among placebo subjects, one diarrhea episode and
one hypoesthesia of the tongue, were of mild intensity
and were judged by the investigator as probably not
related (diarrhea) and possibly related (hypoesthesia) to
the study product. No significant changes were observed
in vital signs, body weight, and results of laboratory tests.
Compliance with the study product was above 90% in
both groups at each time point, with an overall compli-
ance rate of 97%.
Discussion
In this pilot randomized, double-blind, controlled trial,
orally delivered HA in the form of a dietary supplement
appeared to have some efficacy for pain relief in subjects
with osteoarthritis of the knee as shown by within-group
statistically significant changes from baseline to the final
visit in the mean scores for pain subscale of WOMAC
Index and bodily pain subscale of SF-36v2. On the other
hand, scores of the PCS-36 also improved significantly in
the active supplement group.
Although significant within-group differences in the pain
subscales at weeks 4 or 8 compared with baseline were
also observed among subjects given placebo, the magni-
tude of pain relief was higher in the AP arm. With regard
Table 3: Results of the physical health dimension of the SF-36v2 in 16 evaluable subjects
Study groups and time points SF-36v2 scores, mean (SD)
Physical functioning Role-physical Bodily pain General health
Hyal-Joint® (n = 8)
Baseline 31.8 (9.5) 36.1 (9.3) 33.7 (5.5) 48.5 (9.9)
Week 4 34.9 (7.1) 42.2 (7.2) 39.5 (4.5) 46.0 (10.8)
Week 8 34.2 (11.0) 42.8 (6.8) 44.9 (10.1) 51.3 (9.2)
Change baseline vs week 4 3.1 (5.2) 6.1 (3.9) 5.8 (4.7) -2.5 (8.8)
P value 0.137 0.003 0.011 0.444
Change baseline vs week 8 2.4 (5.2) 6.8 (7.8) 11.1 (9.6) 2.8 (9.7)
P value 0.239 0.045 0.013 0.439
Placebo (n = 8)
Baseline 25.5 (7.5) 41.6 (8.3) 36.4 (4.8) 46.5 (10.4)
Week 4 30.5 (9.7) 41.9 (11.6) 39.5 (5.6) 44.4 (8.4)
Week 8 33.1 (9.0) 44.6 (9.3) 38.6 (5.4) 48.4 (7.9)
Change baseline vs week 4 5.0 (5.1) 0.3 (5.6) 3.2 (3.7) -2.1 (4.9)
P value 0.028 0.884 0.045 0.267
Change baseline vs week 8 7.6 (5.2) 3.1 (5.0) 2.2 (4.4) 1.9 (5.5)
P value 0.004 0.129 0.199 0.360
Average change from baseline in SF-36v2 bodily pain score  during the trial (higher is better) (solid symbols = active  product, open symbols = placebo) Figure 1
Average change from baseline in SF-36v2 bodily pain score 
during the trial (higher is better) (solid symbols = active 
product, open symbols = placebo).
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to improvement in health-related quality of life, the active
supplement was also more favorable than placebo in pro-
moting early improvements in the physical function sub-
scale and aggregated total symptoms score of WOMAC, as
shown by within-group statistically significant differences
at 4 weeks. In the role-physical subscale of SF-36v2,
within-group differences at 4 and 8 weeks time points
were only statistically significant in the active supplement
arm. Moreover, the percentage of subjects reporting pain
relief in the AP group was 75% compared to 50% in the
placebo arm. Other randomized, double-blind, placebo-
controlled studies carried out in patients with osteoarthri-
tis of the knee have shown a beneficial effect of nutrition
supplementation with joint specific substances on pain
reduction. After 4 weeks of supplementation with 1500
mg/day of glucosamine sulfate, 52% of patients in the
study group reported an improvement in pain assessed
with the Lequesne's index, while in the placebo group the
percentage of responders was only 37% [25]. Comparable
results were obtained after supplementation with avo-
cado/soybean with 53% of the patients in the study group
judging their treatments as effective compared to only
30% in the placebo group [26]. When the effects of a gin-
ger extract on knee pain in patients with osteoarthritis was
assessed, the percentage of responders experiencing a
reduction in knee pain on standing was 63% in the ginger
extract group versus 50% in the control group [27].
According to these data, the higher magnitude of pain
relief observed in the AP group can be considered mean-
ingful. The preliminary study described herein provides
some evidence, although preliminary, that oral HA is effi-
cacious for reducing pain and subsequently improving
quality of life in adult with knee osteoarthritis.
More subjects in the placebo group (6/9) than in the
active product group (6/11) used rescue medication to
some extent over the course of the study. The placebo
group tended to use twice as much acetaminophen cap-
Table 5: Usage of rescue medication (acetaminophen 500 mg) during the study
Data Study group P value
Hyal-Joint® (n = 11) Placebo (n = 9)
Subjects using rescue medication
Randomization to week 4, n = 12 6 6 1.00
Week 4 to week 8, n = 12 6 6 1.00
Usage during the first 4 weeks
Mean number of capsules (SD) 3.1 (4.2) 6.8 (6.0) 0.172
Capsules per week (range) 1.2 (0 – 12.1) 7 (0 – 16.5)
Usage during the study
Mean number of capsules (SD) 2.0 (3.0) 4.3 (3.6) 0.184
Capsules per week (range) 1.1 (-0.7 – 8.5) 3.6 (0 – 9.5)
Table 4: Results of the mental health dimension of the SF-36v2 in 16 evaluable subjects
Study groups and time points SF-36v2 scores, mean (SD)
Vitality Social functioning Role-emotional Mental health
Hyal-Joint® (n = 8)
Baseline 49.4 (9.9) 38.4 (10.1) 36.9 (10.9) 42.3 (18.8)
Week 4 50.9 (4.4) 46.6 (8.5) 44.2 (5.5) 49.7 (13.3)
Week 8 52.1 (4.7) 43.2 (12.4) 42.3 (10.2) 44.4 (16.3)
Change baseline vs week 4 1.6 (9.9) 8.2 (8.8) 7.3 (7.3) 7.4 (12.2)
P value 0.669 0.033 0.026 0.131
Change baseline vs week 8 2.7 (11.9) 4.8 (12.5) 5.4 (8.8) 2.1 (15.2)
P value 0.537 0.318 0.129 0.707
Placebo (n = 8)
Baseline 49.8 (12.3) 44.6 (11.6) 39.4 (13.4) 48.3 (9.9)
Week 4 49.4 (9.1) 49.3 (8.2) 38.9 (11.6) 49.7 (10.9)
Week 8 53.3 (6.5) 46.6 (8.9) 44.7 (9.6) 52.5 (8.4)
Change baseline vs week 4 -0.4 (8.4) 4.8 (4.5) -0.5 (7.0) 1.4 (9.4)
P value 0.897 0.021 0.843 0.684
Change baseline vs week 8 3.5 (9.3) 2.0 (7.7 5.3 (6.2) 4.2 (9.7)
P value 0.323 0.477 0.045 0.258Nutrition Journal 2008, 7:3 http://www.nutritionj.com/content/7/1/3
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sules as the AP group, but the difference was not statisti-
cally significant, which may be attributable to the small
number of subjects in this pilot study.
The present findings, however, should be interpreted tak-
ing into account the limitations of the study, particularly
the small study population given the exploratory and
pilot characteristics of the trial and the fact that the dura-
tion of the study was limited to 8 weeks. Moreover, the
effects of HA supplementation on joint structure mor-
phology were not assessed. Experimental studies have
shown a stimulatory effect of HA on chondrocyte metab-
olism [28-31]. These stimulating effects could lead to a
permanent improvement on the cartilage if the concentra-
tion of HA could be elevated constantly for a longer
period of time. One possibility to meet a higher demand
caused by a physiological dysfunction is usually the oral
administration of specific nutrients or combinations.
Long-term studies are needed to investigate possible struc-
tural effects of the substance. A further advantage of sup-
plementing patients with joint-specific nutrients is the
long-term efficacy. The reduction of pain associated with
use of NSAIDs in osteoarthritis disappears quickly when
medication is discontinued. Supplementation with joint-
specific nutrients has been shown to produce similar
effects on pain after longer intake, but with persistent
improvements after the end of supplementation
[26,32,33].
Results of this study cannot be compared with data
reported by others. As far as we are aware, no previous
study has examined the clinical impact of oral HA supple-
mentation in subjects with osteoarthritis of the knee.
However, the results appear to build on with prior studies
on intra-articular HA (i.e., Synvisc®, Hyalgan®). Consider-
ing the risks associated with many of the analgesic and
antiinflammatory medications used to treat a chronic
condition, such as osteoarthritis, and side effects associ-
ated with the long-term use of NSAIDs, it is appropriate to
consider the adjunctive use of HA in the therapeutic arma-
mentarium of knee osteoarthritis. This nutritional prod-
uct may be particularly advantageous for elderly subjects
in which osteoarthritis-related pain is a serious limitation
of activities of daily living. Oral HA supplementation may
also offer a benefit over intra-articular HA avoiding poten-
tial complications at the injection site and discomfort
associated with repeated injections [18].
Conclusion
Daily supplementation with HA from a natural extract of
chicken combs (Hyal-Joint®), 80 mg/day for 8 weeks,
appeared to be effective in subjects with knee osteoarthri-
tis for decreasing pain, improving physical function, and
enhancing several aspects of quality of life. Results of this
pilot trial warrant further study in a larger population.
Abbreviations
CI: Confidence interval.
HA: Hyaluronic acid.
NSAIDs: Nonsteroidal antiinflammatory drugs.
LOCF: Last observation carried forward.
MCS-36: Mental component summary-36.
PCS-36: Physical component summary-36.
PP: Per-protocol.
SF-36v2: Short Form-36 Acute US Version 2.
SD: Standard deviation.
WOMAC: Western Ontario and McMaster Universities
Osteoarthritis Index.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
Douglas S. Kalman, MS, RD, FACN, designed the study,
reviewed data, and interpreted results.
Maria Heimer, CCRC, coordinated the study and collected
data.
Anita Valdeon BPS, CCRC, coordinated the study and col-
lected data.
Howard I. Schwartz, MD, FACP, was the sub-investigator
and designed the study.
Eric Sheldon, MD, FACR, was the principal investigator
and designed the study.
All authors reviewed the manuscript and approved the
final draft.
Acknowledgements
Presented as poster at the 47th Annual Meeting of the American College 
of Nutrition, Reno, NV, October 5–8, 2006. We thank Marta Pulido, MD, 
for editing the manuscript and editorial assistance. This study was funded 
via a grant from Bioibérica to Miami Research Associates. The sponsor, Bio-
ibérica, Barcelona, Spain, had no input into the design or execution of the 
study or the preparation of the manuscript.
References
1. Gupta S, Hawker GA, Laporte A, Croxford R, Coyte PC: The eco-
nomic burden of disabling hip and knee osteoarthritis (OA)Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Nutrition Journal 2008, 7:3 http://www.nutritionj.com/content/7/1/3
Page 9 of 9
(page number not for citation purposes)
from the perspective of individuals living with this condition.
Rheumatology (Oxford) 2005, 44:1531-1537.
2. Peat G, McCarney R, Croft P: Knee pain and osteoarthritis in
older adults: a review of community burden.  Ann Rheum Dis
2001, 60:91-97.
3. Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N, Reginster
JY: Direct and indirect costs attributable to osteoarthritis in
active subjects.  J Rheumatol 2006, 33:1152-1158.
4. Dougados M: Why and how to use NSAIDs in osteoarthritis.  J
Cardiovasc Pharmacol 2006, 47(Suppl 1):S49-54.
5. Lo V, Meadows SE, Saseen J: When should COX-2 selective
NSAIDs be used for osteoarthritis and rheumatoid arthritis?
J Fam Pract 2006, 55:260-266.
6. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ: Recom-
mendations for the medical management of osteoarthritis of
the hip and knee. 2000 update. ACR subcommittee on oste-
oarthritis guidelines.  Ann Rheum 2000, 43:1905-1915.
7. Verbruggen G: Chondroprotective drugs in degenerative joint
diseases.  Rheumatology (Oxford) 2005, 45:129-138.
8. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe
P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P,
Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E,
Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G,
Zimmerman-Gorska I, Dougados M, Standing Committee for Interna-
tional Clinical Studies Including Therapeutic Trials ESCISIT: EULAR
Recommendations 2003: an evidence based approach to the
management of knee osteoarthritis: Report of a Task Force
of the Standing Committee for International Clinical Studies
Including Therapeutic Trials (ESCISIT).  Ann Rheum Dis 2003,
62:1145-1155.
9. Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G, Rovati
LC: Glucosamine sulfate use and delay of progression of knee
osteoarthritis. A 3-year, ranzdomized, placebo-controlled,
double-blind study.  Arch Intern Med 2002, 162:2113-2123.
10. Leeb BF, Schweitzer H, Montag K, Smolen JS: A metaanalysis of
chondroitin sulfate in the treatment of osteoarthritis.  J Rheu-
matol 2000, 27:205-211.
11. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O,
Giacovelli G, Henrotin Y, Dacre JE, Gossett C: Long-term effects
of glucosamine sulphate on osteoarthritis progression: a ran-
domised, placebo-controlled clinical trial.  Lancet 2001,
357:251-256.
12. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY:
Structural and symptomatic efficacy of glucosamine and
chondroitin sulfate in knee osteoarthritis. A comprehensive
meta-analysis.  Arch Intern Med 2003, 163:1514-1522.
13. Moreland LW: Intra-articular hyaluronan (hyaluronic acid)
and hylans for the treatment of osteoarthritis: mechanism of
action.  Arthritis Res Ther 2003, 5:54-67.
14. Maneiro E, de Andres MC, Ferández-Sueiro JL, Galdo F, Blanco FJ:
The biological action of hyaluronan on human osteoarthritic
articular chondrocytes: the importance of molecular weight.
Clin Exp Rheumatol 2004, 22:307-312.
15. Ghosh P, Guidolin D: Potential mechanism of action of intra-
articular hyaluronan therapy in osteoarthritis: are the effects
molecular weight dependent?  Semin Arthritis Rheum 2002,
32:10-37.
16. Moskowitz RW: Hyaluronic acid supplementation.  Curr Rev
Rheumatol 2000, 2:466-471.
17. Goldberg VM, Buckwalter JA: Hyaluronans in the treatment of
osteoarthritis of the knee: evidence for disease-modifying
activity.  Osteoarthritis Cartilage 2005, 13:216-224.
18. Adams ME, Lussier AJ, Peyron JG: A risk-benefit assessment of
injections of hyaluronan and its derivatives in the treatment
of knee osteoarthritis.  Drug Saf 2000, 23:115-130.
19. Altman RD, Moskowitz R: Intraarticular sodium hyaluronate
(Hyalgan®) in the treatment of subjects with osteoarthritis
of the knee: a randomized clinical trial.  J Rheumatol 1998,
25:2203-2212.
20. Sun SF, Hsu CW, Hwang CW, Hsu PT, Wang JL, Tsai SL, Chou YJ,
Hsu YW, Huang CM, Wang YL: Hyaluronate improves pain,
physical function and balance in the geriatric osteoarthritic
knee: a 6-month follow-up study using clinical tests.  Osteoar-
thritis Cartilage 2006, 14:696-701.
21. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G: Vis-
cosupplementation for the treatment of osteoarthritis of the
knee.  Cochrane Database Syst Rev 2006, 19(2):CD005321.
22. McAlindon TE: Nutraceuticals: do they work and when should
be use them?  Best Pract Res Clin Rheumatol 2006, 20:99-115.
23. Ameye LG, Chee WS: Osteoarthritis and nutrition. From
nutraceuticals to functional foods: a systematic review of the
scientific evidence.  Arthritis Res Ther 2006, 8:R127. (doi 10.1186/
ar2016)
24. Frech TM, Clegg DO: The utility of nutraceuticals in the treat-
ment of osteoarthritis.  Curr Rheumatol Rep 2007, 9:25-30.
25. Noack W, Fischer M, Förster KK, Rovati LC, Setnikar I: Glu-
cosamine sulfate in osteoarthritis of the knee.  Osteoarthritis
Cartilage 1994, 2:51-59.
26. Maheu E, Mazières B, Valat JP, Loyau G, Le Loët X, Bourgeois P,
Grouin JM, Rozenberg S: Symptomatic efficacy of avocado/soy-
bean unsaponifiables in the treatment of osteoarthritis of
the knee and hip: a prospective, randomized, double-blind,
placebo-controlled, multicenter clinical trial with a six-
month treatment period and a two-month followup demon-
strating a persistent effect.  Arthritis Rheum 1998, 41:81-91.
27. Altman RD, Markussen KC: Effect of ginger extract on knee pain
in subjects with osteoarthritis.  Arthritis Rheum 2001,
44:2431-2538.
28. Patti AM, Gabriele A, Vulcano A, Ramieri MT, Della Rocca C: Effect
of hyaluronic acid on human chondrocytes cell lines from
articular cartilage.  Tissue Cell 2001, 33:294-300.
29. Akmal M, Siingh A, Anand A, Kesani A, Aslam N, Goodship A, Bentley
G: The effects of hyaluronic acid on articular chondrocytes.  J
Bone Joint Surg Br 2005, 87:1143-1149.
30. Gossec L, Dougados M: Do intra-articular therapies work and
who will benefit most?  Best Pract Clin Res Rheumatol 2006,
20:131-144.
31. Gossec L, Dougados M: Intra-articular treatments in osteoar-
thritis: From the symptomatic to the structure modifying.
Ann Rheum Dis 2004, 63:478-482.
32. Mazières B, Loyau G, Menkès CJ, Valat JP, Dreiser RL, Charlot J,
Masounabe-Puyanne A: Chondroitin sulfate in the treatment of
gonarthrosis and coxarthrosis. 5-months result of a multi-
center double-blind controlled prospective study using pla-
cebo.  Rev Rhum Mal Osteoartic 1992, 59:466-472.
33. Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi
L: Comparison of the antiinflammatory efficacy of chondroi-
tin sulfate and diclofenac sodium in patients with knee oste-
oarthritis.  J Rheumatol 1996, 23:1385-1391.